Prelude reports Q3 2026 results, advances KAT6A and JAK2V617F programs
Prelude says cash runway now extends into the second quarter of 2028 as its PRT13722 and PRT12396 trials continue enrolling.
SEC filing (2)
36 stories
Prelude says cash runway now extends into the second quarter of 2028 as its PRT13722 and PRT12396 trials continue enrolling.
SEC filing (2)
FDA offered feedback on a planned Phase 3 study of fasedienol in social anxiety disorder as Vistagen posted a $10.7 million net loss and $20 million in cash as of September 30, 2026.
SEC filing
Twist reported 22% annual revenue growth and positive fourth-quarter adjusted EBITDA, and forecast about 21% revenue growth at the midpoint for fiscal 2027.
SEC filing
Eikon Therapeutics disclosed updated lung cancer data, a registrational trial start, and an IND filing for a new prostate cancer drug, alongside $461.7 million in cash.
SEC filing (12)
ProQR said it expects initial AX-0811 target engagement data in early January 2027 and ended the quarter with €103 million in cash, extending runway into mid-2028.
SEC filing
The agency's action covers locally advanced or metastatic disease, following an earlier accelerated approval for a pediatric RET-altered population.
FDA (5)
The company reported third-quarter 2026 results alongside plans for its first Phase 3 trial site and new executive and board hires ahead of pivotal testing of its oral osteoporosis tablet.
SEC filing
BioAge dosed its first diabetic macular edema patient in September, completed enrollment in its cardiovascular trial, and said cash runs through 2029.
SEC filing
The company reported third-quarter 2026 results alongside an FDA submission, a trial closure expected to save up to $125 million, and $1.15 billion in cash.
SEC filing (14)
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
The company said it has FDA alignment on a registrational path for AATD drug WVE-006 and reported $431.0 million in cash as of September 30, 2026.
SEC filing (7)
The agreements provide free cetuximab supply for a Phase I trial combining Adlai Nortye's investigational ADC AN4035 with the EGFR antibody in RAS-addicted solid tumors.
SEC filing
The agency's drug approvals database lists a new supplemental approval for baricitinib, with a status date of October 9, 2026.
Drugs@FDA
The approval covers adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma who lack a 17p deletion.
FDA, Drugs@FDA (2)
Foghorn Therapeutics said it will not advance FHD-909 with Eli Lilly into expansion after Phase 1 data, and is reducing staff to focus on its own pipeline.
SEC filing
The appointment, effective September 29, 2026, keeps Gregory Weaver as chief financial officer.
SEC filing
The FDA cleared a ninth supplemental application for Olumiant under a standard review, with the approval recorded on September 25, 2026.
Drugs@FDA
The agency's drug database lists the original biologics license application as approved with a status date of September 23, 2026.
Drugs@FDA
The moves are meant to expand AI use across ProQR's Axiomer RNA editing programs, with an early readout for lead AI-discovered candidate AX-0811 expected in January 2027.
SEC filing
The regulator cleared supplement 22 for the abemaciclib tablet application on September 18, 2026, with updated labeling issued days later.
Drugs@FDA
The efficacy supplement for imlunestrant tosylate tablets received FDA approval, with a status date of September 18, 2026.
Drugs@FDA
The neuromedicines company said the hire comes as it heads toward Phase 3 NOVA-2 schizophrenia trial results in the first half of 2027.
SEC filing
Fulk takes over principal financial and accounting officer duties effective September 8, 2026, under an employment agreement with severance terms tied to a change of control.
SEC filing
Luis Jodar joins as CMO and David McAvoy as CLO as Vaxcyte says VAX-31 Phase 3 topline data will arrive by end of October 2026 instead of the fourth quarter.
SEC filing